- Home
- PSBD vs SAGE Comparison
PSBD vs SAGE Comparison
Compare PSBD & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- SAGE
- Stock Information
- Founded
- PSBD 2009
- SAGE 2010
- Country
- PSBD United States
- SAGE United States
- Employees
- PSBD N/A
- SAGE N/A
- Industry
- PSBD
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- PSBD
- SAGE Health Care
- Exchange
- PSBD Nasdaq
- SAGE Nasdaq
- Market Cap
- PSBD 524.9M
- SAGE 462.2M
- IPO Year
- PSBD 2024
- SAGE 2014
- Fundamental
- Price
- PSBD $15.69
- SAGE $5.10
- Analyst Decision
- PSBD Buy
- SAGE Hold
- Analyst Count
- PSBD 7
- SAGE 20
- Target Price
- PSBD $16.93
- SAGE $12.89
- AVG Volume (30 Days)
- PSBD 24.5K
- SAGE 822.5K
- Earning Date
- PSBD 11-05-2024
- SAGE 10-29-2024
- Dividend Yield
- PSBD 11.92%
- SAGE N/A
- EPS Growth
- PSBD N/A
- SAGE N/A
- EPS
- PSBD N/A
- SAGE N/A
- Revenue
- PSBD N/A
- SAGE $106,399,000.00
- Revenue This Year
- PSBD N/A
- SAGE N/A
- Revenue Next Year
- PSBD N/A
- SAGE $118.26
- P/E Ratio
- PSBD N/A
- SAGE N/A
- Revenue Growth
- PSBD N/A
- SAGE 837.60
- 52 Week Low
- PSBD $15.27
- SAGE $5.03
- 52 Week High
- PSBD $17.12
- SAGE $28.26
- Technical
- Relative Strength Index (RSI)
- PSBD 37.99
- SAGE 28.88
- Support Level
- PSBD $15.63
- SAGE $5.86
- Resistance Level
- PSBD $16.07
- SAGE $5.87
- Average True Range (ATR)
- PSBD 0.22
- SAGE 0.51
- MACD
- PSBD -0.02
- SAGE -0.14
- Stochastic Oscillator
- PSBD 8.87
- SAGE 1.91
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.